Journal: | Revista da Associacao Medica Brasileira |
Database: | PERIÓDICA |
System number: | 000307938 |
ISSN: | 0104-4230 |
Authors: | Goncalves, Elsa Alidia Petry1 Manfro, Roberto Ceratti Goncalves, Luiz Felipe Santos Wolffenbüttel, Luciano1 |
Institutions: | 1Universidade Federal do Rio Grande do Sul, Hospital de Clinicas, Porto Alegre, Rio Grande do Sul. Brasil |
Year: | 2003 |
Season: | Abrjun |
Volumen: | 49 |
Number: | 2 |
Pages: | 141-144 |
Country: | Brasil |
Language: | Portugués |
Document type: | Artículo |
Approach: | Caso clínico, analítico |
English abstract | OBJECTIVE: Compare the CsA trough levels of HCV+ kidney transplant recipients to a control group METHODS: All anti-HCV positive patients that received a renal allograft between January 1992 and April 1996 were initially included as cases. Patients with diabetes mellitus, HBsAg+, who were taking medication that could modify CsA pharmacokinetics and those with elevated aminotransferases were excluded. For each anti-HCV positive index case the following transplanted anti-HCV negative patient was included as a control. Third generation ELISA was used for determination of the anti-HCV status and CsA dosages were performed by polarized fluorometry with polyclonal antibodies. RESULTS: No differences in the demographic variables were found. The average CsA through levels in the first month were higher (551 ± 280 ng/ml) in the 23 cases as compared to the 31 controls (418 ± 228 ng/ml; p< 0.05). The differences became apparent at the end of the first week (528 ± 275 versus 344 ± 283 ng/ml; p<0.01) and persisted at discharge (582 ± 284 versus 457 ± 229; p=0,08). CONCLUSION: We concluded that anti-HCV positive patients have higher blood levels of CsA for a particular dosage, than anti-HCV negative controls. Prospective studies with a more appropriate pharmacokinetic approach are needed to confirm the present findings |
Portuguese abstract | OBJETIVO: Comparar os níveis de vale de CsA de transplantados renais anti-HCV+ com um grupo controle. MÉTODOS: Incluímos como casos todos os pacientes anti-HCV+ transplantados entre janeiro de 1992 e abril de 1996, e os anti-HCV- transplantados a seguir do caso como controles. Excluímos pacientes diabéticos, HbsAg+, os que recebiam fármacos com interação com a CsA e aqueles com transaminases elevadas. A sorologia para HCV foi testada pelo método ELISA de 3ª geração, e as dosagens de ciclosporina através de fluorimetria polarizada com anticorpo policlonal. RESULTADOS: As principais variáveis demográficas não diferiram entre os grupos. O nível de vale médio de CsA do primeiro mês pós-transplante foi maior nos 23 pacientes anti-HCV+ (551 ± 280 ng/ml) do que nos 31 controles (418 ± 228 ng/ml, p<0,05). As diferenças tornaram-se aparentes ao final da primeira semana (528 ± 275 versus 344 ± 283 ng/ml; p<0,01) e persistiam no momento da alta (582 ± 284 ng/ml versus 457 ± 229 ng/ml; p=0,08). CONCLUSÃO: Os pacientes anti-HCV+ apresentam níveis de vale de CsA elevados em relação à população controle, o que indica a realização de estudo farmacocinético da droga neste prevalente grupo de transplantados renais |
Disciplines: | Medicina |
Keyword: | Nefrología, Trasplante renal, Ciclosporina A, Hepatitis C, Farmacocinética |
Keyword: | Medicine, Nephrology, Kidney transplantation, Cyclosporine A, Hepatitis C, Pharmacokinetics |
Full text: | Texto completo (Ver HTML) |